AJP - Heart Calcium Transients and Cell-Sarcomere
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 279: H1913-H1921, 2000;
0363-6135/00 $5.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (12)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miller, V. M.
Right arrow Articles by Hurt, R. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miller, V. M.
Right arrow Articles by Hurt, R. D.
Vol. 279, Issue 4, H1913-H1921, October 2000

Time and dose effect of transdermal nicotine on endothelial function

Virginia M. Miller1,2, W. Darrin Clouse1, Britt H. Tonnessen1, Umar S. Boston1, Sandra R. Severson1, Sue Bonde1, Kevin S. Rud1, and Richard D. Hurt3,4

1 Departments of Surgery, 2 Physiology and Biophysics, 3 Internal Medicine, and the 4 Nicotine Research Center, Mayo Clinic and Foundation, Rochester, Minnesota 55905


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

Nicotine patches are available as an over-the-counter medication for aid in smoking cessation. This study was designed to determine how nicotine patch therapy over time and dose ranges used in smoking cessation programs in humans affects endothelium-dependent relaxations. Dogs were treated with nicotine patches (11, 22, or 44 mg/day) for 2 and 5 wk. Circulating nicotine and oxidized products of nitric oxide (NOx) were measured. Coronary arteries were prepared for measurement of isometric force and aortic endothelial cells were prepared for measurement of mRNA or NO synthase (NOS) activity. Circulating nicotine increased with increasing concentrations of nicotine patches. After 5 wk of treatment with 22 mg/day patches, circulating NOx was reduced but NOS activity was increased. NOS mRNA was similar among groups. Only after 5 wk of treatment with 22 mg/day patches were endothelium-dependent relaxations reduced to alpha 2-adrenergic agonists, ADP, and the calcium ionophore A-23187. These results suggest a time and biphasic dose effect of nicotine treatment on endothelium-dependent responses that may be related to bioavailability of NO. This complex relationship of duration and dose of nicotine treatment may explain, in part, discrepancies in effects of nicotine on endothelium-dependent responses.

canine; coronary artery; nitric oxide; nitric oxide synthase


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

SMOKING IS THE LEADING CAUSE of cardiovascular disease, accounting for 30% of cardiac deaths in the United States (12). Nicotine is the addictive component of cigarette smoke (3). However, it should be recognized that harmful cardiovascular effects of cigarette smoke, which contains thousands of known carcinogens, is not equivalent to nicotine consumption (11, 26). Indeed, 2-yr exposure of rats to inhaled nicotine did not result in significant hypertension nor gross vascular or cardiac pathology (48).

Transdermal nicotine is now available over the counter as a therapeutic modality for smoking cessation, making its use less well supervised than when it was a prescription medicine. It is important to understand more fully the effects of transdermal nicotine on vascular function at tissue and cellular levels.

Circulating nicotine could affect vascular function through activation of central and/or peripheral nicotinic receptors associated with sympathetic and parasympathetic fibers to the heart and blood vessels (27). In addition, nicotine could affect vascular function directly through modulation of vascular endothelium (5, 42, 44, 47). Effects of direct infusion or subcutaneous absorption of nicotine on functions of arterial endothelium are controversial, with no changes, increases, and decreases in endothelium-dependent relaxations described (21-23, 25, 26). In human smokers, nicotine nasal spray for smoking cessation may sustain increases in circulating nitric oxide (NO) (29). Differences in responses to nicotine may depend on the anatomic origin of the blood vessels studied and the route of administration, dose, and duration of nicotine exposure. Effects of transdermal nicotine treatment on functions of arterial endothelium are not known; therefore, experiments were designed to determine dose effects of transdermal nicotine on the function of coronary arterial endothelium and aortic endothelial NO synthase (NOS). Transdermal nicotine was tested at doses within and double those used for conventional smoking-cessation programs (7-22 mg) in humans (10). On the basis of other animal studies, it was hypothesized that transdermal nicotine would dose-dependently decrease endothelium-dependent responses in coronary arteries.


    METHODS
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

Animals. Adult male mongrel dogs (20-30 kg) were maintained in accordance with the Principles of Laboratory Animal Care formulated by the National Society for Medical Research and the Guide for the Care and Use of Laboratory Animals prepared by the National Institutes of Health (NIH Publication No. 86-23, Revised 1996). Dogs were either untreated (controls) or treated with transdermal nicotine patches (Lederle Laboratories, Pearl River, NY) of 11, 22, or 44 mg/day (two 22-mg patches) doses. Patches were applied to shaved necks and were changed daily. None of the animals exhibited signs of nicotine toxicity.

Blood samples. To validate systemic absorption of nicotine in treated dogs, nicotine concentration ([nicotine]) and cotinine concentration ([cotinine]), the major metabolite of nicotine, were measured in venous blood before initiation of treatment and again at 6 h (peak) and 24 h (trough) after patch placement. These time points were selected based on previous studies of pharmacokinetics of transdermal nicotine (34). Nicotine was measured in serum by mass spectrometry, and cotinine was measured in plasma by HPLC by the clinical laboratories at Mayo Clinic. An additional 5-ml venous sample was collected for measurement of oxidized products of NO (NOx) by chemiluminescence (9, 29).

Tissue collection. After 2 or 5 wk of treatment, dogs were anesthetized with pentobarbital sodium (30 mg/kg iv) and exsanguinated via the carotid arteries. The heart and a 5-cm segment of descending thoracic aorta were removed from each animal and placed in cold modified Krebs-Ringer bicarbonate solution (control solution) of the following composition (in mM): 118.3 NaCl, 4.7 KCl, 2.5 CaCl2, 1.2 MgSO4, 1.2 KH2PO4, 25.0 NaHCO3, 0.026 calcium disodium edetate, and 11.1 glucose. Left circumflex coronary arteries (LCx) were dissected and prepared for organ-chamber experiments. Because insufficient numbers of endothelial cells could be obtained from the left anterior descending coronary artery, endothelial cells were scraped from each aorta. Aortic endothelial cells were placed immediately in either 1 ml of homogenate buffer [composed of (in mM): 50 Tris · HCl, 320 sucrose, and 0.1 EDTA; and two tablets Complete protease inhibitor (pH 7.8)] for subsequent measurement of NOS, or in 1 ml of RNA STAT-60 (Friendswood, TX) for semiquantitative assessment of mRNA for NOS by RT-PCR. Endothelial cell extracts were snap-frozen in liquid nitrogen and stored at -70°C. Saphenous veins were removed from dogs treated for 5 wk and were studied in separate experiments (8).

Organ-chamber experiments. The LCx was cleaned of connective tissue and cut into four 5-mm rings. The endothelium was removed mechanically by rubbing the intimal surface with forceps. Two pairs of rings with and without endothelium were suspended for measurement of isometric force in organ chambers (25 ml) filled with control solution and bubbled with 95 O2%-5% CO2 at 37°C.

Each ring was stretched to the optimal length as defined by maximal contraction to 20 mM KCl at each incremental level of stretch. All rings were incubated with 10-5 M indomethacin to inhibit cyclooxygenase. After a 30-min equilibration period, maximal contraction to 60 mM KCl was obtained, and one pair of rings with and without the endothelium was incubated with 10-4 M NG-monomethyl-L-arginine (L-NMMA) to inhibit NOS. To study relaxations, rings were contracted with PGF2alpha (2 × 10-6 M), and the test agonist was added cumulatively once the contraction stabilized. The following agonists were tested in the same order for each experiment: alpha 2-adrenergic agonist UK-14304 (10-9-10-6 M), parasympathetic transmitter ACh (10-9-10-5 M), ADP (10-8-10-4 M), calcium ionophore A-23187 (in rings with endothelium, 10-10-10-6 M), and NO (in rings without endothelium, 3 × 10-9-3 × 10-5 M). Rings were rinsed with control solution at least three times between agonists, and inhibitors were re-added to the incubation solution before the next drug was tested. Nicotine was not added exogenously to the incubation solution in any of the organ chambers.

Drugs were obtained from Sigma Chemical (St. Louis, MO) except for UK-14304, which was obtained from Pfizer Central Research (Sandwich, UK). Drugs were prepared daily in distilled water except for A-23187, which was dissolved in DMSO (final bath concentration 8.2 × 10-3 M) and indomethacin, which was prepared in equal molar concentrations of Na2CO3 in distilled water. NO was prepared by the method of Palmer (35). All concentrations are given as the final molar concentration of the drug in the organ chamber.

NOS activity. NOS activity was measured by the stoichiometric conversion of L-[3H]arginine to L-[3H]citrulline. Standard incubation buffer consisted of 5 µM unlabeled L-arginine plus 14.7 nM L-[3H]arginine, 54 mM L-valine, 1.2 mM MgCl2, 1 mM NADPH, 10 µM BH4, 2 µM FAD, 50 U/ml calmodulin, and 50 mM Tris · HCl buffer. Each incubation buffer was subdivided into three tubes, adding either 0.83 mM CaCl2, 1 mM ethylene glycol-EGTA, and 2 mM L-NMMA to respectively assess total, calcium-independent, and nonspecific activity. Exogenous nicotine was not added to any of the incubation buffers. The reaction was started by adding sample homogenates and placing in a shaker bath for 1 h at 37°C. The reaction was terminated by adding 1.5 ml of ice-cold HEPES buffer (pH 5.5). Columns (Poly-Prep chromatography columns, Bio-Rad) were prepared by adding Dowex suspension, which retains the charged species of L-[3H]arginine but allows L-[3H]citrulline to pass through. The elute was collected into Opti-Fluor solution (Packard, Meriden, CT) in scintillation vials. L-[3H]citrulline activity was measured using a Beckman 6800 liquid scintillation counter. NOS activity was expressed as picomoles of L-[3H]citrulline produced per milligram of protein per hour. Calcium-dependent activity was measured as total activity minus calcium-independent activity, correcting for nonspecific activity.

RT-PCR. RT-PCR was performed on total RNA extracted from aortic endothelial cells using RNA STAT-60 reagent (Tel-Test B, Friendswood, TX). The supernatant was removed, and the RNA pellet was washed with 1 ml of 75% ethanol, air dried, and reconstituted in diethylpyrocarbonate (DEPC)-treated water. [RNA] was determined by measuring absorbance at 260 nm in a spectrophotometer (Beckman DU 640, Fullerton, CA). DNase I digestion (amplification grade, Life Technologies, Rockville, MD) of the RNA preparation was performed to eliminate genomic DNA. DNase treatment of 2 µg of total RNA was carried out with 2 µl DNase buffer (200 mM Tris · HCl at pH 8.4, 500 mM KCl, and 20 mM MgCl2) plus 2 µl of amplification grade DNase I (Life Technologies) for 15 min at room temperature. DNase I was then inactivated by heating to 65°C after addition of 2 µl of 25 mM EDTA.

Total RNA was transcribed to cDNA following the manufacturer's instructions and the oligo(dT) priming method. Reverse transcription was performed using SuperScript Preamplification System (Life Technologies) after addition of 1 µl of oligo(dT)12-18 primers to hybridize to 3'-poly(A) tails on mRNA (70°C for 10 min), followed by 7 µl of reaction mixture (2 µl 10× PCR buffer, 2 µl 25 mM MgCl2, 1 µl dNTP mix, and 2 µl 0.1 M dithiothreitol) (42°C for 5 min) and 1 µl SuperScript II RT (42°C for 50 min). The reaction was terminated by heating to 70°C for 15 min followed by incubation with RNase H for 20 min at 37°C. Target cDNA was next amplified by PCR: 35 cycles of denaturation (94°C for 45 s), annealing (60°C for 45 s), and polymerization (72°C for 60 s). The primers used, 5'-TCAACCAGTACTACAGCTCC and 3'-GTGGTTGCAGATGTAGGTGA, detected endothelial cell NOS (ecNOS). A 251-bp product was visualized on 2% agarose gel electrophoresis. Glyceraldehyde-3-phosphate dehydrogenase primers were added to verify the efficiency of cDNA synthesis. Control reactions performed in the absence of RT were negative for genomic DNA.

The cDNA was next quantified using the PCR-MIMIC technique (Clontech, Palo Alto, CA). A MIMIC (nonhomologous internal standard) DNA was constructed by performing two rounds of PCR amplification. In the first reaction two composite primers, 5'-TCAACCAGTACTACAGCTCCCGCAAGTGAAATCTCCTCCG and 3'-GTGGTTGCAGATGTAGGTGATCTGTCAATGCAGTTTGTAG, were used, each containing the target gene primer sequence attached to a nucleotide strand designed to hybridize to opposite strands of a MIMIC DNA fragment. A dilution of this reaction was then amplified again using only the gene-specific primers. The MIMIC DNA was designed to be ~200 bp larger than the target ecNOS PCR product. The MIMIC DNA was next purified by passage through CHROMA SPIN+TE-100 columns, and the yield was calculated by visual comparison of electrophoretic bands generated by the PCR mimic against those generated by a known quantity of marker phiX1741 HAC III DNA and diluted to 100 amol/µl. Competitive PCR amplification was then performed by titrating 1 µl of the target cDNA against serial 10-fold dilutions of the MIMIC DNA, using the eNOS 5'-TCAACCAGTACTACAGCTCC and eNOS 3'-GTGGTTGCAGATGTAGGTGA primers and 35 cycles of denaturation (94°C for 30 s), annealing (63°C for 30 s), and polymerization (72°C for 30 s). The PCR products were analyzed by ethidium bromide-stained 1.6% agarose gel electrophoresis, and bands of cDNA and MIMIC DNA of equal intensity were identified by visual inspection. Fine-tuned competitive PCR was then performed by titrating 1 µl of the target cDNA against serial twofold dilutions of the identified MIMIC DNA dilution in the same manner as described above. The [mRNA] (amol/µl) was determined from the known concentration in the MIMIC DNA band of equal intensity.

Calculations and statistical analysis. All data are expressed as means ± SE; n represents the number of dogs from which arteries or cells were obtained. Effective concentrations causing 50% relaxation (EC50) were calculated for individual rings, and the mean is reported as the logarithm of the molar concentration. Student's t-test for paired observations was used to compare responses between rings with and without the endothelium or in the absence and presence of L-NMMA within animals. When more than two groups were compared, one-way ANOVA was used. If a significant difference was found, Newman-Keuls post hoc test for multiple comparisons was used to identify these differences. Values were considered statistically significant if P < 0.05.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

Blood analysis. Circulating [nicotine] and [cotinine] were not detectable in blood from untreated dogs. With nicotine patching, both [nicotine] and [cotinine] increased 6 h after patching and significantly declined within 24 h only in the 11 mg/day treatment group (Table 1). At 6 h, circulating [nicotine] increased with increasing [nicotine] in the patch (Table 1). Steady-state levels were achieved by 3 wk, an effect that persisted out to 5 wk. [Cotinine] was similar with 11 and 22 mg/day patching and decreased by ~50% during the 24-h period. With 44 mg/day treatment, [cotinine] was significantly elevated compared with other treatment groups at 6 h after patching and decreased by 50% by 24 h.

                              
View this table:
[in this window]
[in a new window]
  		Table 1.   Circulating concentrations of nicotine and cotinine in dogs treated with transdermal nicotine patches for 2 and 5 wk

Circulating [NOx] did not increase significantly over baseline pretreatment levels (10.9 ± 0.8 nM, n = 24) in any group after 2 wk of treatment with nicotine (Table 2). However, after 5 wk of treatment, [NOx] was significantly decreased in dogs treated with 22 mg/day nicotine patches compared with either that measured in untreated dogs or dogs treated with 44 mg/day patches (Table 2).

                              
View this table:
[in this window]
[in a new window]
  		Table 2.   Circulating concentrations of NOx in dogs treated with transdermal nicotine patches for 2 and 5 wk

Organ-chamber experiments. Maximal contractions to KCl (60 mM) were not affected by dose or duration of nicotine patch treatment (Table 3). L-NMMA caused <2 g change in baseline tension in rings with endothelium from any group.

                              
View this table:
[in this window]
[in a new window]
  		Table 3.   Contractions in coronary arteries with endothelium from untreated dogs and dogs treated with transdermal nicotine patches

Endothelium-dependent relaxations to the alpha 2-adrenergic agonist were concentration dependent and were not altered significantly by dose of nicotine patching at 2 wk of treatment (Fig. 1). After 5 wk of treatment, variability among relaxations to UK-14304 was significantly increased, and maximal relaxations in rings from dogs treated with 22 mg/day patches were less than those from untreated dogs and from dogs treated with 44 mg/day patches (Fig. 1). Incubation of arteries with L-NMMA significantly inhibited relaxations in all groups to the same extent (Fig. 1).


View larger version (29K):
[in this window]
[in a new window]
  		Fig. 1.   Concentration-dependent relaxations to the alpha 2-adrenergic agonist UK-14304 in rings of left circumflex coronary arteries (LCx) with endothelium from untreated dogs and dogs treated with transdermal nicotine for 2 wk (A) or 5 wk (B). UK-14304 did not cause relaxation of rings without endothelium, and these responses are omitted for clarity. Responses are shown in absence and presence of NG-monomethyl-L-arginine (L-NMMA). Data are shown as means ± SE (n = 6-8 dogs at 2 wk and 5-6 at 5 wk) and are expressed as percent change in tension from contraction to PGF2alpha (2 × 10-6 M). There were no significant differences in contractions among arteries in 2-wk or 5-wk treatment groups (Table 3). Experiments were conducted in presence of indomethacin (10-5 M). There were no significant differences in relaxations among groups from 2-wk treated dogs. In 5-wk treated dogs, maximal relaxations were significantly decreased in rings from dogs treated with 22 mg/day compared with those from untreated dogs and dogs treated with 44 mg/day patches. L-NMMA significantly inhibited relaxations to UK-14304 in arteries from all groups. *Statistically significant difference, P < 0.05.

ACh also caused concentration-dependent relaxations in all arteries with endothelium (Fig. 2). These relaxations were not altered statistically by nicotine treatment after 2 or 5 wk. Incubation of rings with L-NMMA to inhibit NO caused comparable rightward log shifts in all groups (data not shown, n = 5-7 in all groups).


View larger version (20K):
[in this window]
[in a new window]
  		Fig. 2.   Concentration-dependent relaxations to ACh in rings of LCx arteries with endothelium from untreated dogs and dogs treated with transdermal nicotine for 2 wk (A) or 5 wk (B). ACh did not cause relaxations in rings without endothelium and these responses are omitted for clarity. Data are shown as means ± SE (n = 5-7 dogs in all groups) and are expressed as percent change in tension from a contraction to PGF2alpha (2 × 10-6 M). Experiments were conducted in presence of indomethacin (10-5 M). There were no significant differences in relaxations among groups after 2 or 5 wk of treatment. L-NMMA significantly shifted relaxations to the right in all groups of arterial segments for both 2- and 5-wk treated dogs (not shown, n = 6-8 dogs in all groups).

ADP caused greater relaxation of rings with endothelium compared with rings without endothelium (Fig. 3). In rings with endothelium, relaxations to ADP were significantly shifted to the right of responses from rings from untreated dogs only after 5 wk of treatment with 22 mg/day patches (Fig. 3). After 5 wk of treatment, relaxations to ADP of rings with endothelium from dogs treated with 11 and 22 mg/day patches were shifted by L-NMMA to a greater extent than those from dogs treated with 44 mg/day patches (Fig. 4).


View larger version (26K):
[in this window]
[in a new window]
  		Fig. 3.   Concentration-dependent relaxations to ADP in rings of LCx arteries with and without endothelium from untreated dogs and dogs treated with transdermal nicotine for 2 (A) or 5 wk (B). Data are shown as means ± SE (n = 5-7 dogs per group) and are expressed as a percent change in tension from contractions to PGF2alpha (2 × 10-6 M). There were no significant differences in contractions to PGF2alpha . Experiments were conducted in the presence of indomethacin (10-5 M). Removal of endothelium significantly reduced maximal relaxations to ADP in all groups. In the 2-wk treatment group, there were no statistically significant differences in relaxations among rings with endothelium. However, with 5 wk of treatment, relaxations of rings from dogs treated with 22 mg/day patches were shifted to the right of these untreated dogs. *Statistical significance of EC50, P < 0.05.



View larger version (23K):
[in this window]
[in a new window]
  		Fig. 4.   Concentration-dependent relaxations to ADP of rings of LCx arteries with endothelium in the presence of L-NMMA (10-4 M) from untreated dogs and dogs treated with nicotine patches for 2 (A) and 5 wk (B). Data are shown as means ± SE (n = 5-7 dogs per group) and are expressed as percent change in tension from contractions to PGF2alpha (2 × 10-6 M). There were no significant differences in contractions to PGF2alpha . Experiments were conducted in the presence of indomethacin (10-5 M). In the presence of L-NMMA, relaxations to ADP in rings from dogs treated with 11 and 22 mg/day nicotine patches for 5 wk were significantly shifted to the right of rings from untreated dogs and dogs treated with 44 mg/day. *Significance of EC50, P < 0.05.

Relaxations of rings with endothelium to the calcium ionophore A-23187 from dogs treated with 22 and 44 mg/day nicotine patches for 5 wk were shifted to the right of responses from untreated dogs and dogs treated with 11 mg/day patches (Fig. 5). Incubation of the rings with L-NMMA caused comparable rightward shifts in all responses (data not shown, n = 6-8 per group). NO caused comparable concentration-dependent relaxations of rings without endothelium in all groups (Table 4).


View larger version (20K):
[in this window]
[in a new window]
  		Fig. 5.   Concentration-dependent relaxations to calcium ionophore A-23187 in rings of LCx arteries with endothelium from untreated dogs and dogs treated with transdermal nicotine for 2 wk (A) or 5 wk (B). Data are shown as means ± SE (n = 6-8 dogs per group) and are expressed as percent change in tension from contraction to PGF2alpha (2 × 10-6 M). Experiments were conducted in the presence of indomethacin (10-5 M). In the 2-wk treatment group, there were no significant differences in relaxations among groups. In the 5-wk treatment group, relaxations were significantly shifted to the right in the group of arterial segments from dogs treated with 22 mg/day nicotine patches. *Significance of EC50, P < 0.05.


                              
View this table:
[in this window]
[in a new window]
  		Table 4.   Mean EC50 relaxation to NO in coronary artery rings without endothelium from untreated dogs and dogs treated with transdermal nicotine

NOS activity. Neither total nor calcium-dependent NOS activity differed among NOS derived from aortic endothelial cells of untreated dogs or dogs treated with transdermal nicotine for 2 wk. However, after 5 wk of treatment, total and calcium-dependent NOS activity was significantly greater (P < 0.01) in cells isolated from dogs treated with 22 mg/day patches compared with activity in cells from dogs treated with 11 and 44 mg/day patches (Fig. 6). Calcium-independent and nonspecific activities were not affected after either 2 or 5 wk treatment with nicotine patches.


View larger version (19K):
[in this window]
[in a new window]
  		Fig. 6.   Calcium-dependent activity of nitric oxide synthase (NOS) isolated from untreated dogs and dogs treated with transdermal nicotine for 2 wk (A) or 5 wk (B). NOS activity was determined by conversion of L-[3H]arginine to L-citrulline. Activity is expressed as percentage of calcium-dependent NOS activity from untreated dogs (100%). Values are means ± SE, n = number of dogs from which enzyme was isolated. Calcium-dependent NOS activity after 2 wk of transdermal treatment was not significantly different among untreated dogs and dogs treated with 11, 22, and 44 mg/day nicotine patches. However, after 5 wk of treatment, calcium-dependent NOS activity was less in cells from dogs treated with 11 and 44 mg/day patches than those treated with 22 mg/day patches. *Difference from 22 mg/day, ANOVA, P < 0.01.

mRNA. There were no statistically significant differences in mRNA for NOS in aortic endothelial cells from untreated dogs or dogs treated with transdermal nicotine for 5 wk (Fig. 7).


View larger version (16K):
[in this window]
[in a new window]
  		Fig. 7.   Quantization of mRNA by MIMIC for NOS from aortic endothelial cells [endothelial NOS (eNOS)] of untreated dogs or dogs treated with transdermal nicotine for 5 wk. Data are shown as means ± SE of cells from untreated dogs (n = 6) and dogs with transdermal nicotine (n = 3 per group). Each assay from cells of nicotine-treated dogs was performed in duplicate.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

Results of this study indicate for the first time that effects of transdermal nicotine treatment on coronary arterial endothelial function are dependent on time and duration of nicotine patch treatment and the agonist used to stimulate the endothelial cells.

Nicotine dosing was within the range and double to that commonly used in smoking cessation programs (10). This resulted in serum [nicotine] within the range measured in humans undergoing nicotine patch therapy for standard smoking cessation therapy (range from 8-30 ng/ml with the 22 mg/day dosing) (1, 34). Plasma levels of nicotine in smokers range from 10.5-50 ng/ml nicotine (17, 34). Individual levels vary by weight, metabolism, and absorption. Cotinine, a major metabolite of nicotine, is measured frequently in humans as an indicator of nicotine exposure. Circulating levels of cotinine were elevated with nicotine treatment but were lower in dogs than in humans treated with comparable doses of nicotine. Cotinine is psychobiologically inactive but its effects on the vasculature have not been defined. Therefore, it is not known at this time if cotinine, especially in animals treated with 44 mg/day patches, would antagonize effects of nicotine.

Two weeks of treatment with nicotine (11-44 mg/day) patches did not alter endothelium-dependent relaxations in canine coronary arteries. These results are consistent with results from studies using a similar duration of nicotine treatment in rats (22, 23). However, results are in contrast with results found in hamster cheek-pouch arterioles, where nicotine treatment for 2 wk reduced endothelium-dependent relaxations (26). The difference in results could reflect differences in the endothelium of conduit compared with resistance arteries and final circulating [nicotine] or that the present studies were conducted in the presence of indomethacin. Indomethacin inhibits cyclooxygenase, a major source of reactive oxygen radical species, which could reduce the bioavailability of NO. Indeed, in hamster cheek-pouch arterioles, endothelium-dependent relaxations were restored in nicotine-treated arteries when concentrations of oxygen-derived free radical were reduced by simultaneous administration of superoxide dismutase (26).

After 5 wk of treatment with transdermal nicotine, endothelium-dependent relaxations were reduced but the degree of inhibition was dependent on the agonist tested and the dose of nicotine treatment. For example, endothelium-dependent relaxations were most consistently inhibited in arteries from dogs treated with 22 mg/day nicotine. At this dose, circulating NOx was also reduced. Therefore, decreased endothelium-dependent relaxations are consistent with decreased release or bioavailability of NO from endothelial cells. At first these observations seem in contradiction with the augmentation of NOS activity in extracts of aortic endothelial cells from these dogs. However, increases in the amount and activity of the enzyme may reflect an upregulation due to decreased bioavailability of the end-product NO (expressed as decreased endothelium-dependent relaxations), which acts as a negative feedback regulator to reduce activity of the enzyme in the cell (15, 38). A limitation of this conclusion is that enzyme activity was not measured directly in coronary endothelial cells. However, despite this limitation, the results point to posttranscriptional regulation of NOS and NO with nicotine treatment for several reasons. First, mRNA for NOS was similar among groups. Second, if nicotine regulated NOS transcriptionally, then it might be expected for all endothelium-dependent responses to be uniformly reduced in dogs treated with 22 mg/day patches. This was not the case, because there was not a significant inhibition of relaxations to ACh. Posttranscriptional regulation of NOS may be through production of oxygen-derived free radicals (26), although direct scavenging of free radicals by superoxide dismutase was not tested in the coronary arteries from nicotine-treated dogs. Alternatively, unpublished observations from our laboratory suggest that nicotine may interact with NOS indirectly through interaction with oxygen radicals (47a). It is unlikely that arginine availability was limiting for NOS activity as inducible NOS was not increased significantly with nicotine treatment.

In addition to possible direct interactions of nicotine with cellular processes, nicotine could alter endothelium-dependent relaxations through indirect mechanisms associated with activation of autonomic ganglia and release of neurotransmitters including ACh, norepinephrine, and NO (27, 45-47, 49). Such an indirect effect may explain why relaxations to alpha 2-adrenergic stimulation with UK-14304 were reduced but dependent on the dose of nicotine treatment. Adrenergic receptors may be downregulated in response to increased release of adrenergic transmitter (7, 13). Although adrenergic receptors were not quantified in arteries from nicotine-treated dogs, stimulation of sympathetic neurons by nicotine may affect adrenergic receptor number and affinity. Nicotine treatment may also affect receptor-coupled regulatory proteins that stimulate NOS. alpha 2-Adrenergic endothelium-dependent relaxations are associated with guanine nucleotide regulatory proteins which are inhibited by pertussis toxin (14, 28). These responses are sensitive to modulation by hypercholesterolemia and allotransplant rejection (36, 40). Endothelium-dependent relaxations initiated by ACh, which are insensitive to inhibition by pertussis toxin, were not significantly affected by nicotine treatment at any dose. This may reflect that ACh releases other endothelium-derived factors in addition to NO (6, 20, 32, 33).

There appears to be a biphasic dose relationship of nicotine treatment on selective endothelium-dependent responses. This conclusion is based on the observations that responses to UK-14304 and ADP were less sensitive in arteries from dogs treated with 22 mg/day patches but similar among arteries from untreated dogs and dogs treated with 11 and 44 mg/day nicotine. A similar biphasic dose-response relationship of nicotine treatment with endothelium-dependent responses was observed in saphenous veins from these same dogs (8) and in saphenous veins used as coronary artery bypass grafts (9). The mechanism of this biphasic effect of treatment dose is unclear. Nicotine may stimulate NOS directly (47a) or via specific receptor-coupled mechanisms for release of NO (8). Alternatively, because responses to the direct release of endothelium-derived factors by the calcium ionophore were inhibited similarly in coronary arteries from dogs treated with either 22 or 44 mg/day doses, other endothelium-derived factors not measured in this study could have been affected by the nicotine treatment (2, 5, 26, 41, 42). Whether this represents compensatory mechanisms similar to those associated with "nicotine tolerance" (2, 16) or antagonism of nicotine by cotinine remains to be determined. The observation of a complex dose relationship between nicotine and endothelium responses explains in part discrepancies in the literature regarding changes in vascular responses with nicotine.

Differences among studies in regard to effects of nicotine on endothelial function also may relate to the method by which nicotine was delivered. In the present study, circulating [nicotine] was cyclic with increases in concentrations within 6 h after application of a new patch and slow decline throughout the day. This pattern would correspond to that in humans using nicotine patches for smoking cessation therapy (1, 4, 17) and contrasted to other patterns obtained with either inhalation [which would result in rapid peaks (48)] or subcutaneous delivery by osmotic minipump [which would result in sustained levels (2, 16, 22, 23, 25, 26)].

In summary, results of this study provide direct evidence that treatment with transdermal nicotine alters endothelium-dependent responses in nondiseased coronary arteries in a time- and dose-dependent manner. Furthermore, whether or not an inhibition of endothelium-dependent relaxations was observed depended on the agonist used to elicit the response and the duration of treatment. How these changes in endothelial function observed in vitro affect coronary arterial function in vivo remains to be determined. However, smoking is a known risk factor for coronary artery disease in humans and adversely affects endothelial function (12, 18, 31, 39). Smoking cessation is known to reduce the risk for subsequent disease (12). Conventional nicotine patch therapy is safe for use in smokers with known coronary artery disease (19, 30, 50). In addition, inhalation of nicotine for up to 2 yr in rats did not result in gross arterial or coronary pathology (48). Therefore, it is likely that transdermal nicotine can continue to be used to aid smoking cessation with minimal detrimental effects (24, 37, 43). Results also caution against using general statements regarding effects of nicotine on endothelial function and its mechanism of action without attention to blood vessels studied, mode of delivery (tobacco or nontobacco; continuous or phasic; inhalation, intravenous, or cutaneous), dose, and duration of nicotine treatment.


    ACKNOWLEDGEMENTS

This work was supported in part by American Heart Association Grant 96-010290 and the Mayo Foundation.


    FOOTNOTES

Present address of W. D. Clouse: Wilford Hall Medical Center, Department of General Surgery, 59th MDW/MMKG, 2200 Bergquist Ave., Suite 1, Lackland AFB, TX 78236-5300.

Present address of B. H. Tonnessen: Department of Surgery, Alton Ochsner Foundation Hospital, 1516 Jefferson Highway, New Orleans, LA 70121.

Address for reprint requests and other correspondence: V. M. Miller, Dept. of Surgery, Mayo Clinic and Foundation, 200 First St. SW, Rochester, MN 55905 (E-mail: miller.virginia{at}mayo.edu).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 2 February 2000; accepted in final form 5 April 2000.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

1.   Bannon, YB, Corish J, Corrigan OI, Devane JG, Kavanagh M, and Mulligan S. Transdermal delivery of nicotine in normal human volunteers: a single-dose and multiple-dose study. Eur J Clin Pharmacol 37: 285-290, 1989[ISI][Medline].

2.   Bassenge, E, Holtz J, and Strohschein H. Sympathoadrenal activity and sympathoinhibitory hormones during acute and chronic nicotine application in dogs. Klin Wochenschr 66: 12-20, 1988.

3.   Benowitz, NL, and Jacob P. Intravenous nicotine replacement suppresses nicotine intake from cigarette smoking. J Pharmacol Exp Ther 254: 1000-1005, 1990[Abstract/Free Full Text].

4.   Benowitz, NL, Jacob P, Fong I, III, and Gupta S. Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. J Pharmacol Exp Ther 268: 296-303, 1994[Abstract/Free Full Text].

5.   Bull, HA, Pittilo RM, Woolf N, and Machin SJ. The effect of nicotine on human endothelial cell release of prostaglandins and ultrastructure. Br J Exp Pathol 69: 413-421, 1988[ISI][Medline].

6.   Chataigneau, T, Feletou M, Huang PL, Fishman MC, Duhault J, and Vanhoutte PM. Acetylcholine-induced relaxation in blood vessels from endothelial nitric oxide synthase knockout mice. Br J Pharmacol 126: 219-226, 1999[ISI][Medline].

7.   Chien, CY. Nicotine-induced skeletal muscle vasodilation is mediated by release of epinephrine from nerve terminals. Am J Physiol Heart Circ Physiol 259: H1718-H1729, 1990[Abstract/Free Full Text].

8.   Clouse, WD, Rud KS, Hurt RD, and Miller VM. Short-term treatment with transdermal nicotine affects function of canine saphenous veins. Vasc Med 5: 75-82, 2000[Abstract/Free Full Text].

9.   Clouse, WD, Yamaguchi H, Phillips MR, Hurt RD, Fitzpatrick LA, Moyer TP, Rowland C, Schaff HV, and Miller VM. Transdermal nicotine and coronary artery bypass grafts: effects on structure and function. J Appl Physiol 89: 1213-1223, 2000[Abstract/Free Full Text].

10.   Dale, LC, Hurt RD, Offord KP, Lawson GM, Croghan IT, and Schroeder DR. High-dose nicotine patch therapy. Percent replacement and smoking cessation. JAMA 27: 1353-1358, 1995.

11.   Deliconstantinos, G, Villiotou V, and Stavrides JC. Scavenging effects of hemoglobin and related heme containing compounds on nitric oxide, reactive oxidants, and carcinogenic volatile nitrosocompounds of cigarette smoke. A new method for protection against the dangerous cigarette constituents. Anticancer Res 14: 2717-2726, 1994[ISI][Medline].

12.   US Department of Health and Human Services. . In: The Health Benefits of Smoking Cessation: A Report of the Surgeon General. DHHS Publication CDC 90-8416. Centers for Disease Control, 1990.

13.   Downey, HF, Williams AGJ, Yonekura S, Watanabe N, and Lawrence ME. Dominant role of circulating catecholamines in the myocardial contractile response to intravenous nicotine. J Cardiovasc Pharmacol 12: 58-64, 1988[ISI][Medline].

14.   Flavahan, NA, Shimokawa H, and Vanhoutte PM. Pertussis toxin inhibits endothelium-dependent relaxations to certain agonists in porcine coronary arteries. J Physiol (Lond) 408: 549-560, 1988[Abstract/Free Full Text].

15.   Griscavage, JM, Hobbs AJ, and Ignarro LJ. Negative modulation of nitric oxide synthase by nitric oxide and nitroso compounds. Adv Pharmacol 34: 215-234, 1995.

16.   Holtz, J, Sommer O, and Bassenge E. Development of specific tolerance to nicotine infusions in dogs on chronic nicotine treatment. Klin Wochenschr 62: 51-57, 1984.

17.   Hurt, RD, Dale LC, Offord KP, Lauger GG, Baskin LB, Lawson GM, Jiang N-S, and Hauri PJ. Serum nicotine and cotinine levels during nicotine-patch therapy. Clin Pharmacol Ther 54: 98-106, 1993[ISI][Medline].

18.   Jorge, PA, Ozaki MR, and Almeida EA. Endothelial dysfunction in coronary vessels and thoracic aorta of rats exposed to cigarette smoke. Clin Exp Pharmacol Physiol 22: 410-413, 1995[ISI][Medline].

19.   Khoury, Z, Comans P, Keren A, Lerer T, Gavish A, and Tzivoni D. Effects of transdermal nicotine patches on ambulatory ECG monitoring findings: a double-blind study in healthy smokers. Cardiovasc Drugs Ther 10: 179-184, 1996[ISI][Medline].

20.   Komori, K, and Vanhoutte PM. Endothelium-derived hyperpolarizing factor. Blood Vessels 27: 238-245, 1990[ISI][Medline].

21.   Krause, DN, and Dubocovich ML. Melatonin receptors. Annu Rev Pharmacol Toxicol 31: 549-568, 1991[ISI][Medline].

22.   Li, Z, Barrios VE, Buchholz JN, Glenn TC, and Duckles SP. Chronic nicotine administration does not affect peripheral vascular reactivity in the rat. J Pharmacol Exp Ther 271: 1135-1142, 1994[Abstract/Free Full Text].

23.   Li, Z, and Duckles SP. Acute effects of nicotine on rat mesenteric vasculature and tail artery. J Pharmacol Exp Ther 264: 1305-1310, 1993[Abstract/Free Full Text].

24.   Lucini, D, Bertocchi F, Malliani A, and Pagani M. Autonomic effects of nicotine patch administration in habitual cigarette smokers: a double-blind, placebo-controlled study using spectral analysis of RR interval and systolic arterial pressure variabilities. J Cardiovasc Pharmacol 31: 714-720, 1998[ISI][Medline].

25.   Mayhan, WG, and Patel KP. Effect of nicotine on endothelium-dependent arteriolar dilatation in vivo. Am J Physiol Heart Circ Physiol 272: H2337-H2342, 1997[Abstract/Free Full Text].

26.   Mayhan, WG, and Sharpe GM. Chronic exposure to nicotine alters endothelium-dependent arteriolar dilatation: effect of superoxide dismutase. J Appl Physiol 86: 1126-1134, 1999[Abstract/Free Full Text].

27.   McPhail, I, Boston U, Hurt RD, and Miller VM. Mechanisms of cardiovascular effects of nicotine. Curr Top Pharmacol 4: 265-280, 1998.

28.   Miller, VM, Flavahan NA, and Vanhoutte PM. Pertussis toxin reduces endothelium-dependent and independent responses to alpha 2-adrenergic stimulation in systemic canine arteries and veins. J Pharmacol Exp Ther 257: 290-293, 1991[Abstract/Free Full Text].

29.   Miller, VM, Lewis DA, Rud KS, Offord KP, Croghan IT, and Hurt RD. Plasma nitric oxide before and after smoking cessation with nicotine nasal spray. J Clin Pharmacol 38: 22-27, 1998[Abstract].

30.   Muller, P, Imhof P, Mauli D, and Milovanovic D. Human pharmacological investigations of a transdermal nicotine system. Methods Find Exp Clin Pharmacol 11: 197-204, 1989[ISI][Medline].

31.   Murohara, T, Kugiyama K, Ohgushi M, Sugiyama S, and Yasue H. Cigarette smoke extract contracts isolated porcine coronary arteries by superoxide anion-mediated degradation of EDRF. Am J Physiol Heart Circ Physiol 266: H874-H880, 1994[Abstract/Free Full Text].

32.   Nagao, T, and Vanhoutte PM. Hyperpolarization as a mechanism for endothelium-dependent relaxations in the porcine coronary artery. J Physiol (Lond) 445: 355-367, 1992[Abstract/Free Full Text].

33.   O'Donnell, SR, Wanstall JC, Kay CS, and Zeng X. Tissue selectivity and spasmogen selectivity of relaxant drugs in airway and pulmonary vascular smooth muscle contracted by PGF2alpha or endothelin. Br J Pharmacol 102: 311-316, 1991[ISI][Medline].

34.   Palmer, KJ, Buckley MM, and Faulds D. Transdermal nicotine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an aid to smoking cessation. Drugs 44: 498-529, 1992[ISI][Medline].

35.   Palmer, RM, Ferrige AG, and Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327: 524-526, 1987[Medline].

36.   Perrault, LP, Bidouard JP, Janiak P, Villeneuve N, Bruneval P, Vilaine JP, and Vanhoutte PM. Impairment of G-protein-mediated signal transduction in the porcine coronary endothelium during rejection after heart transplantation. Cardiovasc Res 43: 457-470, 1999[Abstract/Free Full Text].

37.   Pickworth, WB, Bunker EB, and Henningfield JE. Transdermal nicotine: reduction of smoking with minimal abuse liability. Psychopharmacology (Berl) 115: 9-14, 1994[Medline].

38.   Ravichandran, LV, Johns RA, and Rengasamy A. Direct and reversible inhibition of endothelial nitric oxide synthase by nitric oxide. Am J Physiol Heart Circ Physiol 268: H2216-H2223, 1995[Abstract/Free Full Text].

39.   Rubinstein, I, Yong T, Rennard SI, and Mayhan WG. Cigarette smoke extract attenuates endothelium-dependent arteriolar dilatation in vivo. Am J Physiol Heart Circ Physiol 261: H1913-H1918, 1991[Abstract/Free Full Text].

40.   Shimokawa, H, Flavahan NA, and Vanhoutte PM. Loss of endothelial pertussis toxin-sensitive G protein function in atherosclerotic porcine coronary arteries. Circulation 83: 652-660, 1991[Abstract/Free Full Text].

41.   Shirahase, H, Usui H, Kurahashi K, Fujiwara M, and Fukui K. Endothelium-dependent contraction induced by nicotine in isolated canine basilar artery: possible involvement of a thromboxane A2 (TXA2)-like substance. Life Sci 42: 437-445, 1988[ISI][Medline].

42.   Suzuki, N, Ishii Y, and Kitamura S. Effects of nicotine on production of endothelin and eicosanoid by bovine pulmonary artery endothelial cells. Prostaglandins Leukot Essent Fatty Acids 50: 193-197, 1994[ISI][Medline].

43.   Thomas, GAO, Davies SV, Rhodes J, Russell MAH, Feyerabend C, and Sawe U. Is transdermal nicotine associated with cardiovascular risk? J R Coll Physicians Lond 29: 392-396, 1995[ISI][Medline].

44.   Toda, N. Nicotine-induced relaxation in isolated canine cerebral arteries. J Pharmacol Exp Ther 193: 376-384, 1975[Abstract/Free Full Text].

45.   Toda, N, Kitamura Y, and Okamura T. Role of nitroxidergic nerve in dog retinal arterioles in vivo and arteries in vitro. Am J Physiol Heart Circ Physiol 266: H1985-H1992, 1994[Abstract/Free Full Text].

46.   Toda, N, and Okamura T. Reciprocal regulation by putatively nitroxidergic and adrenergic nerves of monkey and dog temporal arterial tone. Am J Physiol Heart Circ Physiol 261: H1740-H1745, 1991[Abstract/Free Full Text].

47.   Toda, N, and Okamura T. Regulation by nitroxidergic nerve of arterial tone. News Physiol Sci 7: 148-152, 1992[Abstract/Free Full Text].

47a.  Tonnessen, BH, Severson SR, Hurt RD, and Miller VM. Modulation of nitric oxide synthase (NOS) by nicotine. J Pharmacol Exp Therap. In press.

48.   Waldum, HL, Nilsen OG, Nilsen T, Syversen U, Sandvik AK, Haugen OA, Torp SH, and Brenna E. Long-term effects of inhaled nicotine. Life Sci 58: 1339-1346, 1996[ISI][Medline].

49.   Woodman, OL. Coronary vascular responses to nicotine in the anaesthetized dog. Naunyn Schmiedebergs Arch Pharmacol 343: 65-69, 1991[ISI][Medline].

50.   Working Group for the Study of Transdermal Nicotine in Patients with Coronary Artery Disease. . Nicotine replacement therapy for patients with coronary artery disease. Arch Intern Med 154: 989-995, 1994[Abstract].

Am J Physiol Heart Circ Physiol 279(4):H1913-H1921
0363-6135/00 $5.00 Copyright © 2000 the American Physiological Society


This article has been cited by other articles:


Home page
 J. Appl. Physiol.Home page
D. M. Arrick and W. G. Mayhan
Acute infusion of nicotine impairs nNOS-dependent reactivity of cerebral arterioles via an increase in oxidative stress
J Appl Physiol, December 1, 2007; 103(6): 2062 - 2067.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
Q. Fang, H. Sun, D. M. Arrick, and W. G. Mayhan
Inhibition of NADPH oxidase improves impaired reactivity of pial arterioles during chronic exposure to nicotine
J Appl Physiol, February 1, 2006; 100(2): 631 - 636.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
F. Moccia, C. Frost, R. Berra-Romani, F. Tanzi, and D. J. Adams
Expression and function of neuronal nicotinic ACh receptors in rat microvascular endothelial cells
Am J Physiol Heart Circ Physiol, February 1, 2004; 286(2): H486 - H491.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
Q. Fang, H. Sun, and W. G. Mayhan
Impairment of nitric oxide synthase-dependent dilatation of cerebral arterioles during infusion of nicotine
Am J Physiol Heart Circ Physiol, February 1, 2003; 284(2): H528 - H534.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
T. P. Moyer, J. R. Charlson, R. J. Enger, L. C. Dale, J. O. Ebbert, D. R. Schroeder, and R. D. Hurt
Simultaneous Analysis of Nicotine, Nicotine Metabolites, and Tobacco Alkaloids in Serum or Urine by Tandem Mass Spectrometry, with Clinically Relevant Metabolic Profiles
Clin. Chem., September 1, 2002; 48(9): 1460 - 1471.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
C. E. Black, N. Huang, P. C. Neligan, R. H. Levine, J. E. Lipa, S. Lintlop, C. R. Forrest, and C. Y. Pang
Effect of nicotine on vasoconstrictor and vasodilator responses in human skin vasculature
Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2001; 281(4): R1097 - R1104.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (12)
Right arrow Citing Articles via Google Scholar
Google Scholar